Restoring the function  of joint surfaces using  tissueengineering

Thanks to the PEARL procedure, performed at an early stage of the development of the degenerative disease, it will be possible to completely regenerate the cartilage.
learn more
Thanks to the regeneration of cartilage defects, the disease will not progress and the need for arthroplasty (implantation of a joint endoprosthesis) will not occur.
learn more
Innovative Method
Proven results
Experienced Team
Patented therapy

No effective strategy for treatment young, active patients with cartilage leasions.

in 2030

The first THA (total hip arthroplasty) performed in younger patients will constitute 52%

The first TKA (total knee arthroplasty) 55%

Osteoarthritis (OA)

Is a disease characterized by joint  pain and dysfunction caused by  the progressive and irreversible  loss of joint cartilage.


At an advanced stage of the  disease, it becomes necessary  touseanendoprosthesis.Removal  of the joint means its permanent  destruction and the  final  loss  of periarticular bone tissue.

In the case of disease progression and  periimplant tissue degeneration,the next  stage is an even more extensive excision of the tissues and theimplantation

of larger implant – which usually ends with a permanent disabilityafter revision  surgeries.

By 2050

130 million patients will be suffering

from osteoarthritis

40 million will be disabled

It is significant that the disease affects  younger and younger patients,  analyzing data so far

Value of the global endoprosthesis market:

2019 - USD 19.32 billion
2027 - USD 29.79 billion
5.6% CAGR

Global cartilage reconstruction market value:

2022 - USD 984,25 mln
2030 - USD 3 095,64 mln
15,4% CAGR

There is no effective therapy for degenerative joint disease

Worldwide, 9.6% of men and 18% of women over the age of 60 have symptoms of osteoarthritis.

80% of them suffer from limited movement  and 25% areunable to perform basic life  activities.

Disadvantages of existing solutions

Disadvantages of traditional methods (endoprostheses)

The prosthesis does not rebuild into tissue. Its implantation destroys bone and cartilage irreversibly.

Progressive tissue lysis around the endoprosthesis.

Inability to fill and restore the tissue after loosening the implant.

In the case of peri-prosthetic fractures, it is necessary to replace with extensive damage to the bones and surrounding tissues.

Endoprosthesis loosening - revisions of endoprostheses lead to the loss of bone tissue and surrounding structures, which results in permanent disability.

Inability to reproduce the full range of motion. Inability to return to full fitness.

Hip prosthesis - risk of dislocation, Hip and knee prosthesis - complex periprosthetic bone fractures.

Age and health restrictions.

Significant risk of infection (not only perisurgical).

The need for revision surgery that appears along with the implantation of an endoprosthesis in younger age groups 45-55 (1- 3 per patient) - increased risk of complications.

Disadvantages of available biological methods

Lack of technology to restore full-thick and stable hyaline cartilage.

Limited effectiveness compared to traditional methods (endoprothesis).

Possibility to treat small cartilage defects.

Unknown effectiveness in people over 55 years of age.

High cost of therapy.

In the United States, only 0.4% of all surgically treated patients undergo regenerative treatment , but this group is gradually growing.

First Round - Completed
  • Objectives – optimizationand validation of the method.
  • Acquired capital – EUR 230 thousand.
  • Duration of work – 8 quarters.
Second Round - Present
  • Objectives – conducting research hospital exception (HEATMP) and clinical trial preparation.
  • Capital demand – EUR 230 thousand.
  • Duration of work – 4 quarters.
Third Round
  • Objectives – clinical tial and ATMP registration
  • Capital demand EUR 3.8 million
  • Duration of work – 14 quarters

meet Our Experienced team

Marek Putko

Chairman of the Board
A graduate of the Medical University in Gdańsk.

MBA - University of Gdansk, Universiteit Antwerpen RUCA, Copenhagen Business School, Fachhochschule Fur Technik und Wirtschaft in Berlin.

A manager with 30 years experience in sales and marketing, very good knowledge pharmaceutical market, practical experience in leading human resources, creating development strategy and sales of products, implementing marketing message.

For 30 years associated with the pharmaceutical and medical industry.

He participated in the creating and implementation of many innovative projects and products on the market.

Experience gained in many large international corporation and Polish local producers.

Wojciech Armuła

Chief Financial Officer

Graduate of the Kraków University of Economics.

Completed post-graduate studies in Accounting and Finance for the Advanced offered by the Kraków School of Business, which is a part of the Kraków University of Economics.

External expert for the Ministry of Energy (since 2016) and the Institute of Oil and Gas (since 2009) with respect to financial aspects of energy projects. Between 2009 and 2015, he was an expert of the Małopolska Center for Entrepreneurship (an assessor in terms of investment operations of enterprises).

Coach of the European Commission (EASME, the Horizon 2020 SME Instrument), providing financial consulting and coaching to SMEs.

Took active part in a number of IPOs and SPOs on the Warsaw Stock Exchange including NewConnect.

Focusing in corporate finance, mainly valuations of companies, business plans, feasibility studies.

Prof. Ph.D. Justyna Drukała

Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University in Krakow, academic teacher

Manager of the Tissue and Cell Bank and the ATMP Plant (responsible person under the Act of July 1, 2005 on the collection, storage and transplantation of cells, tissues and organs, qualified person under the Act of September 6, 2001 - Pharmaceutical Law).

Pioneer in the field of tissue engineering in Poland, specializes in the cultivation of skin cells - advanced therapy medicinal products for use in the treatment of severe burns (National Transplantation Program).
Conducts research on the regenerative potential of skin cells and cartilage cells.

Author of over 70 experimental and review publications.

Member of the National Transplantation Council (Development Strategy Team) and the Expert Committee of the Polish Burn Treatment Society

Dr Grzegorz Sobieraj

A graduate of the Faculty of Medicine at the

Medical University of Lodz.

Orthopedics and traumatology specialist.

Member of the ESSKA , ICRS ,ESSSE , Polish Arthroscopic Society, Polish Orthopedic Society.

A pioneer in the field of innovative joint operating procedures.

Manager of the PCZ Orthopedic

Department in Brzeziny.

Medical Director of the Medical Hospital of the St. John of God Hospital in Łódź.

Head pshysician of the orthopedic ward in the Ortho Sport Clinic Private Hospital in Poland.

Iwona Makowska

A graduate of the Faculty of Chemistry at the University of Technology of Warsaw.

For 17 years works in the clinical trials industry.

Experience in leading multiple global projects in Pharmacovigilance Department.

Experience in monitoring visits from start-up to close-out as Senior Clinical Research Associate.

Experience in managing clinical projects.

Experience in developing study specific documents.

Holds the European Medicines Agency certificates for EudraVigilance – electronic reporting of ICSRs and extended EudraVigilance Medicinal Product Dictionary (xEVMPD).

Experience in global submission to Regulatory Agencies and Ethics Committees.

Agnieszka Stochmal

A graduate of the Maritime Academy (Faculty of Navigation) and the WSB University in Gdańsk (Faculty of Finance and Management).

Manager with over 15 years of experience in the capital market.

Co-founder of three capital funds with a total capitalization exceeding 50 million PLN.

Responsible for the entire investment and divestment process, portfolio supervision, and fund finances.

Her extensive experience also includes project management and the financial and substantive monitoring of projects.

Starodworska 1
80-180 Gdansk, Poland